218 related articles for article (PubMed ID: 29649593)
21. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
22. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
[TBL] [Abstract][Full Text] [Related]
23. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.
Watanabe I; Ross TM; Tamura S; Ichinohe T; Ito S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
Vaccine; 2003 Nov; 21(31):4532-8. PubMed ID: 14575764
[TBL] [Abstract][Full Text] [Related]
24. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
25. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
26. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
[TBL] [Abstract][Full Text] [Related]
27. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms.
Chen CY; Liu HJ; Tsai CP; Chung CY; Shih YS; Chang PC; Chiu YT; Hu YC
Vaccine; 2010 Nov; 28(48):7644-51. PubMed ID: 20883735
[TBL] [Abstract][Full Text] [Related]
28. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.
Deng L; Kim JR; Chang TZ; Zhang H; Mohan T; Champion JA; Wang BZ
Virology; 2017 Sep; 509():82-89. PubMed ID: 28622575
[TBL] [Abstract][Full Text] [Related]
29. Salmonella flagellin enhances mucosal immunity of avian influenza vaccine in chickens.
Chaung HC; Cheng LT; Hung LH; Tsai PC; Skountzou I; Wang B; Compans RW; Lien YY
Vet Microbiol; 2012 May; 157(1-2):69-77. PubMed ID: 22226542
[TBL] [Abstract][Full Text] [Related]
30. Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice.
Kim H; Kimoto T; Sakai S; Takahashi E; Kido H
PLoS One; 2018; 13(1):e0191133. PubMed ID: 29370185
[TBL] [Abstract][Full Text] [Related]
31. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
[TBL] [Abstract][Full Text] [Related]
32. Mucosal and Systemic Immune Responses to Influenza H7N9 Antigen HA1-2 Co-Delivered Intranasally with Flagellin or Polyethyleneimine in Mice and Chickens.
Song L; Xiong D; Song H; Wu L; Zhang M; Kang X; Pan Z; Jiao X
Front Immunol; 2017; 8():326. PubMed ID: 28424686
[TBL] [Abstract][Full Text] [Related]
33. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
34. Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses.
Wang Z; Gao J; Yu Q; Yang Q
Future Microbiol; 2012 Aug; 7(8):1003-10. PubMed ID: 22913358
[TBL] [Abstract][Full Text] [Related]
35. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
36. An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin.
Song L; Xiong D; Kang X; Yang Y; Wang J; Guo Y; Xu H; Chen S; Peng D; Pan Z; Jiao X
BMC Biotechnol; 2015 Aug; 15():79. PubMed ID: 26286143
[TBL] [Abstract][Full Text] [Related]
37. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
38. Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine.
Fan XT; Wang YL; Su QD; Qiu F; Yi Y; Jia ZY; Wang DY; Qin K; Zou YN; Bi SL; Shen LP
Biomed Environ Sci; 2019 Jul; 32(7):531-540. PubMed ID: 31331437
[TBL] [Abstract][Full Text] [Related]
39. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
[TBL] [Abstract][Full Text] [Related]
40. Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes.
Li R; Chowdhury MY; Kim JH; Kim TH; Pathinayake P; Koo WS; Park ME; Yoon JE; Roh JB; Hong SP; Sung MH; Lee JS; Kim CJ
Vet Microbiol; 2015 Sep; 179(3-4):250-63. PubMed ID: 26210951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]